

National Organization for Rare Disorders, Inc.®



NORD • 100 Rt. 37, P.O. Box 8923 • New Fairfield, CT 06812-8923
(203) 746-6518 • FAX : (203) 746-6481
<http://www.nord-rdb.com/~orphan> • e-mail: orphan@nord-rdb.com

March 26, 1999

6953 '99 MAR 30 P2:11

Dockets Management Branch
(HFA-305)
Food & Drug Administration
5630 Fishers Lane, Room 1061
Rockville, MD 20852

Re: Docket No. 99N-0336
Talking With Stakeholders About
FDA Modernization

Dear Sirs:

The National Organization for Rare Disorders (NORD) is unable to attend the April 28 meeting and teleconference to discuss the agency's progress on implementing FDAMA and seeking input from stakeholders. We are therefore submitting the following written comments in response to the *Federal Register* notice of March 22, 1999.

NORD represents an estimated 20 million Americans with rare "orphan diseases." As a representative of the patient community, we are primarily concerned about the speedy availability of safe and effective drugs, biologics, devices and medical foods. We feel the communication efforts of the FDA can be greatly improved so that the patient community will have better access to understandable information about experimental and approved therapeutics, including the risks and benefits of marketed products.

1. In response to question 1, the agency can expand its capability to incorporate state-of-the-art science into its risk-based decision making by providing more hands on training of FDA personnel. This may include laboratory research, FDA personnel's participation in the commercial production of regulated products, on-going education and training, etc. However, as part of this training FDA personnel should be required to spend some time in the clinic to learn the realities of clinical trials and sensitize them to patient needs.

99N-0386

C2

MEMBER ORGANIZATIONS

Alliance of Genetic Support Groups
Alpha 1 Antitrypsin Deficiency
National Association
ALS Association
American Brain Tumor Association
American Porphyria Association
American Society of Adults with
Pseudo-obstruction, Inc. (ASAP)
American Syringomyelia Alliance Project
Aplastic Anemia Foundation of America
Association for Glycogen Storage Disease
Batten Disease Support & Research
Association
Benign Essential Blepharospasm Research
Foundation, Inc.
Charcot-Marie-Tooth Association
Chromosome 18 Registry and
Research Society
Cornelia de Lange Syndrome
Foundation, Inc.
Cystinosis Foundation, Inc.
Dysautonomia Foundation, Inc.
Dystonia Medical Research Foundation
Dystrophic Epidermolysis Bullosa Research
Association (D.E.B.R.A.)
Ehlers-Danlos National Foundation
Epilepsy Foundation of America
Families of Spinal Muscular Atrophy
Fanconi Anemia Research Fund, Inc.
Foundation Fighting Blindness
Foundation for Ichthyosis & Related
Skin Types (F.I.R.S.T.)
Guillain-Barre Syndrome Foundation
International
HHT Foundation International, Inc.
Hemochromatosis Foundation, Inc.
Hereditary Disease Foundation
Histiocytosis Association of America
Human Growth Foundation
Huntington's Disease Society of
America, Inc.
Immune Deficiency Foundation
International Fibrodysplasia Ossificans
Progressiva (FOP) Association, Inc.
International Joseph Diseases
Foundation, Inc.
International Rett Syndrome Association
Interstitial Cystitis Association of
America, Inc.
Lowe's Syndrome Association
Malignant Hyperthermia Association
of the United States
Myasthenia Gravis Foundation
Myeloproliferative Disease Center
Myositis Association of America
Mucopolidosis Type IV Foundation (ML4)
Narcolepsy Network, Inc.
National Adrenal Diseases Foundation
National Alopecia Areata Foundation
National Ataxia Foundation
National Chronic Fatigue Syndrome and
Fibromyalgia Association
National Foundation for Ectodermal
Dysplasias
National Hemophilia Foundation
National Marfan Foundation
National Mucopolysaccharidoses Society, Inc.
National Multiple Sclerosis Society
National Neurofibromatosis Foundation
National PKU News
National Sjogren's Syndrome Association
National Spasmodic Torticollis Association
National Tay-Sachs & Allied Diseases
Association, Inc.
National Tuberos Sclerosis Association, Inc.
National Urea Cycle Disorders Foundation
Neurofibromatosis, Inc.
Obsessive Compulsive Foundation
Osteogenesis Imperfecta Foundation
Oxalosis and Hyperoxaluria Foundation
Paget Foundation
Parkinson's Disease Foundation, Inc.
Prader-Willi Syndrome Association
Pulmonary Hypertension Association
PXE International, Inc.
Reflex Sympathetic Dystrophy Syndrome
Association
Scleroderma Foundation, Inc.
Sickle Cell Disease Association of
America, Inc.
Tourette Syndrome Association, Inc.
Trigeminal Neuralgia Association
United Leukodystrophy Foundation, Inc.
United Mitochondrial Disease Foundation
United Parkinson Foundation
VHL Family Alliance
Wegener's Granulomatosis Support
Group, Inc.
Williams Syndrome Association
Wilson's Disease Association

Associate Members

Acid Maltase Deficiency Association
Acicardi Syndrome Newsletter, Inc.
ALS Association/Greater Philadelphia
Chapter
American Autoimmune Related Diseases
Association
American Behcet's Disease Association,
Inc.
American Laryngeal Papilloma
Foundation
American Pseudo-obstruction &
Hirschsprung's Disease Society, Inc.
American Self-Help Clearinghouse
Androgen Insensitivity Group

Angelview Crippled Children's Foundation
A-T Project
Ataxia Telangiectasia Children's Project
CDGS Family Network
Canadian Organization for Rare Disorders
Center for Research in Sleep Disorders
Children's Hospital Medical Center, Akron
Ohio
Children's Leukemia Foundation/Michigan
Children's Medical Library
Children's PKU Network
Chronic Granulomatous Disease
Association, Inc.
Consortium of Multiple Sclerosis Centers
Contact A Family

Cooley's Anemia Foundation
Cushing Support & Research Foundation
Earl Goldberg Aplastic Anemia Foundatin
Family Caregiver Alliance
Family Support System for North Carolina
Footsteps Institute
Freeman-Sheldon Parent Support Group
International Foundation for Alternating
Hemiplegia of Childhood
JUMP Foundation
Klippel-Trenaunay Support Group
Late Onset Tay-Sachs Foundation
Les Turner ALS Foundation, Inc.

National Association for Pseudoxanthoma
Elasticum
National CPL Foundation
National Coalition for Research in
Neurological & Communicative Disorders
National Incontinentia Pigmenti Foundation
National Niemann-Pick Disease
Foundation
National Oral Health Information
National Patient Air Transport Hotline
National Spasmodic Dysphonia Association
Neutropenia Support Association
Organic Acidemia Association
Osteoporosis and Related Bone Diseases
National Resource Center

Parents Available to Help (PATH)
Parent to Parent of Georgia, Inc.
Parent to Parent of New Zealand
Recurrent Respiratory Papillomatosis
Foundation
Research Trust for Metabolic Diseases in
Children/United Kingdom
Restless Legs Syndrome Foundation
Sarcoid Networking Association
Shwachman Syndrome Support Group
Shy Drager Support Group
Sickle Cell Disease Association of Texas
Gulf Coast
Society For Supranuclear Palsy, Inc.
Sotos Syndrome Support Association

Sturge-Weber Foundation
Teacher Collins Foundation
Vaincre les Maladies Lysosomales/France
Washington State Parents for Vocational
Education (PAVE)
Wegener Health Information Center

* Associations are joining continuously.
For newest listing, please contact the
NORD office.

FDA is often criticized for its insensitivity to patients, especially when the agency requires placebo controlled trials for fatal diseases. While such decisions are easy to make on Fishers Lane, they are not easily complied with in a hospital (especially when children are involved). FDA personnel should be exposed to the realities of medical practice so they can understand that the agency's decisions should not be made in a vacuum, and they should always consider the human implications of their directives. In this context, we highly recommend that the agency hire at least one bioethicist who can participate in protocol design, review and amend informed consent documents, and provide oversight of clinical trials. The agency should have an internal IRB that will wrestle with ethical questions.

2. Regarding question 2, the implications of any delay in exchange of information between FDA and the patient community can be profound. We are baffled when we hear about a serious adverse effect of a marketed drug, as to why weeks or months can go by before the information is added to the drug's label. We hear that FDA is "discussing" possible label amendments with the drug sponsor, or "negotiating" label changes. If FDA's primary mission is to protect and enhance the public's health, there should be no negotiation; FDA should tell the drug sponsor to change the label. There should be no delay and no discussion if patients are at risk. FDA's public health role is compromised when the agency appears to be serving the interests of pharmaceutical or device companies rather than the interests of the public.
3. This question asks how the agency can better educate the public about the risk/benefit ratio of marketed products. We believe the first step in the process is for FDA to stop categorizing virtually every piece of information about regulated products as a "trade secret." For example, if a patient asks if there is an experimental drug for their disease, FDA is not permitted to say whether an IND has been filed because such information is a "trade secret." Nor is FDA permitted to say whether a drug is in phase II or phase III trials, nor whether an NDA or PLA has been submitted. While such information is kept secret at the agency, Wall Street investors know virtually everything about these products including where they are in the research pipeline, when the company will file an NDA, and what the results of the clinical trials have shown to date. Thus, the patient community is denied information that the investor community already knows. Patients should not have to file a *Freedom of Information* request to get information that companies have already disclosed elsewhere.

Moreover, the FDA does not currently have the authority to require manufacturers to amend even blatantly outrageous informed consent documents, and the agency should seize this authority in order to assure that investigators and companies are communicating accurately with potential participants in human trials.

It is also incumbent on the FDA to require all manufacturers to print understandable labeling information; package inserts and labeling printed in books such as the PDR are not helpful to people who have not received a scientific education. To deny patients understandable information about drug side effects and possible interactions is immoral and unethical, but this is the current situation for modern consumers.

4. The patient community is very sensitive to the extraordinary resource limitations of the FDA. It is imperative that sufficient resources are made available to assure that the agency can adequately carry out all responsibilities of its mandate. We are especially concerned that post-marketing surveillance activities, adverse event monitoring, generic drugs, foods, cosmetics, inspections, importation and medical device programs are suffering due to the focus of FDA resources on new drug development activities.

We suggest it was wrong for the agency not to implement user fees on new drugs until the pharmaceutical industry agreed to the fees. It is therefore wrong for the agency to avoid implementation of user fees on other industries simply because those industries do not want to pay. Public health is not enhanced by delayed availability of generic drugs, devices, etc. In other countries regulatory agencies charge user fees without the permission and consent of regulated industries. FDA should do likewise for generic drugs, devices, foods, cosmetics, veterinary drugs, etc. Congress will never give the agency sufficient resources to do everything it needs for the protection of public health, so user fees appear to be the pragmatic answer to this long-term problem.

5. Additional actions that we propose to enhance communication processes include absolute deadlines for FDA officials to answer questions from the public; it is not unusual for consumers to wait many months to receive an answer to a letter sent to the FDA. Too many times the FDA does not answer consumers' questions because the agency determines that a truthful answer is a "trade secret." FDA personnel are generally unaware that the public is a stakeholder, and the public deserves timely and accurate answers. In general, consumers do not ask questions that would violate intellectual property rights; they just want answers affecting their personal health (or the health of a loved one) that have nothing to do with patents. The agency must respond to the public appropriately for the sake of public health. For example, consumers sometimes express anger against the agency for not approving a new drug, but the agency will not freely reveal that the drug is not approved because an NDA has not been filed.

Additionally, the agency must act on the public's behalf to require label changes (without the manufacturers consent), require doctors and hospitals to report adverse effects, require withdrawal of dangerous products (such as nutritional supplements), and in general protect the public health even when a regulated industry disagrees. There are times when consumers feel that the public is more regulated by the FDA than are the industries that the agency is supposed to be monitoring. When a member of the public is told to write a Freedom of Information letter in order to find out if a certain side effect has been reported for a specific drug, we are being regulated rather than the manufacturer of the drug.

I do hope these comments are helpful in understanding the public's frustration with the FDA. We sincerely appreciate the Commissioner's stakeholder meetings which provide an opportunity to the public to make their views known to the agency.

Very truly yours,



Abbey S. Meyers
President

ASM:aa

cc: Sharon Smith Holston
Deputy Commissioner for External Affairs




*out of the darkness
into the light®*

FORWARDING AND RETURN
POSTAGE GUARANTEED
ADDRESS CORRECTION
REQUESTED

National Organization for Rare Disorders, Inc.®

NORD • P.O. BOX 8923 • New Fairfield, CT 06812-8923

CFC# 0551



|||||
Dockets Management Branch
(HFA-305)
Food & Drug Administration
5630 Fishers Lane, Room 1061
Rockville, MD 20852

